|
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.
|
J Cachexia Sarcopenia Muscle
38500292
|
0 |
8.9 |
2024 |
|
The impact of myelosuppression on quality of life of patients treated with chemotherapy.
|
Future Oncol
38587388
|
0 |
3.3 |
2024 |
|
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
|
N Engl J Med
37870974
|
16 |
158.5 |
2023 |
|
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.
|
Clin Cancer Res
37982848
|
1 |
11.5 |
2023 |
|
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
|
J Natl Cancer Inst
36625510
|
2 |
10.3 |
2023 |
|
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.
|
ESMO Open
36905787
|
2 |
6.883 |
2023 |
|
Adapting to Change: A Thoracic Oncology Team's Perspective.
|
JCO Oncol Pract
37307517
|
0 |
4 |
2023 |
|
Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer.
|
Clin Lung Cancer
37055337
|
0 |
3.6 |
2023 |
|
The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps.
|
Curr Opin Oncol
37222193
|
0 |
3.4 |
2023 |
|
Two decades of pegfilgrastim: what have we learned? Where do we go from here?
|
Curr Med Res Opin
36976784
|
0 |
2.3 |
2023 |
|
Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop.
|
J Cachexia Sarcopenia Muscle
35218313
|
6 |
8.9 |
2022 |
|
Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer.
|
J Cachexia Sarcopenia Muscle
36268548
|
2 |
8.9 |
2022 |
|
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
|
Oncologist
35552754
|
4 |
5.8 |
2022 |
|
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
|
Lung Cancer
36442383
|
0 |
5.3 |
2022 |
|
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
|
Support Care Cancer
35426046
|
0 |
3.1 |
2022 |
|
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
|
Support Care Cancer
35732748
|
2 |
3.1 |
2022 |
|
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD.
|
J Comp Eff Res
36378570
|
0 |
2.1 |
2022 |
|
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.
|
JTO Clin Res Rep
35719867
|
0 |
1.4 |
2022 |
|
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
|
J Immunother Cancer
34429332
|
12 |
12.469 |
2021 |
|
RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.
|
Lung Cancer
33465699
|
4 |
6.081 |
2021 |
|
Role of dietary carbohydrates on risk of lung cancer.
|
Lung Cancer
33756357
|
6 |
6.081 |
2021 |
|
Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis.
|
Oncologist
33973301
|
16 |
5.837 |
2021 |
|
Effect of ischemia-reperfusion on outcomes after open mesenteric bypass for chronic mesenteric ischemia.
|
J Vasc Surg
33887424
|
1 |
4.86 |
2021 |
|
Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung.
|
Clin Lung Cancer
33582071
|
0 |
4.84 |
2021 |
|
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
|
BMC Cancer
34044798
|
2 |
4.638 |
2021 |
|
Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life.
|
Patient Prefer Adherence
33658769
|
3 |
2.314 |
2021 |
|
Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage.
|
Cancer Treat Res Commun
34655862
|
2 |
0.01 |
2021 |
|
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
|
J Thorac Oncol
32540409
|
18 |
15.609 |
2020 |
|
Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.
|
Oncologist
33098189
|
0 |
5.837 |
2020 |
|
Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
|
Lung Cancer
31926983
|
5 |
5.705 |
2020 |
|
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.
|
Adv Ther
32642965
|
18 |
3.845 |
2020 |
|
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
|
N Engl J Med
30786186
|
204 |
74.699 |
2019 |
|
Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.
|
JAMA Psychiatry
30624573
|
54 |
17.471 |
2019 |
|
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
|
J Thorac Oncol
31887431
|
35 |
15.609 |
2019 |
|
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
|
J Thorac Oncol
31158500
|
27 |
13.357 |
2019 |
|
High Availability of the α7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using F-ASEM PET.
|
J Nucl Med
31420499
|
8 |
10.057 |
2019 |
|
Sarcopenia: A Time for Action. An SCWD Position Paper.
|
J Cachexia Sarcopenia Muscle
31523937
|
174 |
9.802 |
2019 |
|
Therapeutic outcomes in non-small cell lung cancer with mutations: a single institution, retrospective cohort study.
|
Transl Lung Cancer Res
31367539
|
5 |
5.132 |
2019 |
|
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.
|
Support Care Cancer
31172284
|
17 |
3.603 |
2019 |
|
What are the criteria for response to cachexia treatment?
|
Ann Palliat Med
30685983
|
18 |
1.681 |
2019 |
|
Addressing oncologists' gaps in the use of biosimilar products.
|
Am J Manag Care
31233307
|
0 |
1.679 |
2019 |
|
Hybrid management approach for superior mesenteric artery and branch aneurysms.
|
J Vasc Surg Cases Innov Tech
31909308
|
2 |
0 |
2019 |
|
Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States.
|
J Thorac Oncol
30312680
|
16 |
12.46 |
2018 |
|
Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.
|
J Thorac Oncol
29981438
|
7 |
12.46 |
2018 |
|
The availability of the α7 nicotinic acetylcholine receptor in recent-onset psychosis: a study using F-ASEM PET.
|
J Nucl Med
30573639
|
9 |
7.354 |
2018 |
|
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
|
Oncologist
29572245
|
11 |
5.252 |
2018 |
|
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.
|
Crit Rev Oncol Hematol
30097240
|
3 |
5.012 |
2018 |
|
Contemporary outcomes of thoracofemoral bypass.
|
J Vasc Surg
30292606
|
4 |
3.405 |
2018 |
|
Tibial artery duplex ultrasound-derived peak systolic velocities may be an objective performance measure after above-knee endovascular therapy for arterial stenosis.
|
J Vasc Surg
29523435
|
0 |
3.243 |
2018 |
|
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.
|
Clin Breast Cancer
29622384
|
20 |
2.762 |
2018 |
|
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
|
J Thorac Oncol
28161554
|
19 |
10.336 |
2017 |
|
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
|
Clin Cancer Res
28951518
|
34 |
10.199 |
2017 |
|
Developments in Molecular Testing and Biosimilars.
|
J Natl Compr Canc Netw
28596257
|
1 |
6.471 |
2017 |
|
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
29223990
|
51 |
6.471 |
2017 |
|
Cancer cachexia: Are we ready to take a step forward?
|
Cancer
29205293
|
1 |
6.102 |
2017 |
|
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
|
Oncologist
28188257
|
2 |
5.306 |
2017 |
|
Overcoming obstacles in the design of cancer anorexia/weight loss trials.
|
Crit Rev Oncol Hematol
28807233
|
13 |
4.495 |
2017 |
|
Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia.
|
Clin Lung Cancer
29233611
|
16 |
4.117 |
2017 |
|
Intraluminal thrombus is associated with early rupture of abdominal aortic aneurysm.
|
J Vasc Surg
29141786
|
30 |
3.243 |
2017 |
|
Phase I study of pazopanib plus TH-302 in advanced solid tumors.
|
Cancer Chemother Pharmacol
28238078
|
6 |
2.808 |
2017 |
|
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
|
Support Care Cancer
28939926
|
23 |
2.754 |
2017 |
|
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.
|
Ann Oncol
27436850
|
42 |
11.855 |
2016 |
|
Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.
|
Lung Cancer
27393510
|
15 |
4.294 |
2016 |
|
Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall.
|
Clin Lung Cancer
27965012
|
3 |
4.204 |
2016 |
|
Clinical results in cachexia therapeutics.
|
Curr Opin Clin Nutr Metab Care
26974316
|
8 |
4.023 |
2016 |
|
Aortic outflow occlusion predicts rupture of abdominal aortic aneurysm.
|
J Vasc Surg
27374068
|
6 |
3.536 |
2016 |
|
Arterial duplex for diagnosis of peripheral arterial emboli.
|
J Vasc Surg
27374063
|
2 |
3.536 |
2016 |
|
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
|
Curr Oncol Rep
27138015
|
64 |
2.608 |
2016 |
|
Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein are Increased in Peripheral Artery Disease.
|
J Cardiovasc Transl Res
26891844
|
33 |
2.319 |
2016 |
|
Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
|
Cancer Invest
27911119
|
11 |
2.053 |
2016 |
|
Treatment of Lung Cancer in Medically Compromised Patients.
|
Am Soc Clin Oncol Educ Book
27249757
|
3 |
0 |
2016 |
|
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
|
J Clin Oncol
26169616
|
269 |
24.008 |
2015 |
|
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
|
J Clin Oncol
25732163
|
63 |
24.008 |
2015 |
|
Request for regulatory guidance for cancer cachexia intervention trials.
|
J Cachexia Sarcopenia Muscle
26675232
|
57 |
9.697 |
2015 |
|
The Natural History of Indeterminate Blunt Cerebrovascular Injury.
|
JAMA Surg
26200995
|
10 |
7.956 |
2015 |
|
A Comparison of Breast-Specific Gamma Imaging of Invasive Lobular Carcinomas and Ductal Carcinomas.
|
JAMA Surg
26107618
|
0 |
7.956 |
2015 |
|
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
|
J Thorac Oncol
26723241
|
4 |
6.595 |
2015 |
|
Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.
|
Lung Cancer
26319317
|
3 |
4.294 |
2015 |
|
Outcomes of unilateral graft limb excision for infected aortobifemoral graft limb.
|
J Vasc Surg
26482992
|
1 |
3.536 |
2015 |
|
Characterization of tibial velocities by duplex ultrasound in severe peripheral arterial disease and controls.
|
J Vasc Surg
26620716
|
2 |
3.536 |
2015 |
|
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
|
Cancer Med
25810005
|
8 |
3.362 |
2015 |
|
Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma.
|
Leuk Lymphoma
25926064
|
3 |
2.755 |
2015 |
|
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
|
Support Care Cancer
26370220
|
23 |
2.698 |
2015 |
|
Genetics, Pregnancy, and Aortic Degeneration.
|
Ann Vasc Surg
26381327
|
4 |
1.145 |
2015 |
|
Management of catheter-associated upper extremity deep venous thrombosis.
|
J Vasc Surg Venous Lymphat Disord
27318061
|
2 |
1.143 |
2015 |
|
The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.
|
Springerplus
26251780
|
4 |
0 |
2015 |
|
A review of relative dose intensity and survival in patients with metastatic solid tumors.
|
Crit Rev Oncol Hematol
25459671
|
47 |
4.971 |
2014 |
|
Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?
|
J Natl Compr Canc Netw
24853225
|
0 |
4.675 |
2014 |
|
Inhibition of murine fibrocyte differentiation by cross-linked IgG is dependent on FcγRI.
|
J Leukoc Biol
24752483
|
3 |
4.018 |
2014 |
|
A modern series of acute aortic occlusion.
|
J Vasc Surg
24393282
|
23 |
3.536 |
2014 |
|
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.
|
Cancer Med
24706592
|
38 |
3.362 |
2014 |
|
Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents.
|
Expert Rev Hematol
25081548
|
3 |
2.246 |
2014 |
|
Tumor acquisition for biomarker research in lung cancer.
|
Cancer Invest
24810245
|
1 |
2.218 |
2014 |
|
Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.
|
Pract Radiat Oncol
25413417
|
2 |
1.503 |
2014 |
|
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
|
Lancet Oncol
23680111
|
80 |
33.9 |
2013 |
|
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
|
J Thorac Oncol
24389433
|
6 |
6.595 |
2013 |
|
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
|
J Thorac Oncol
23715301
|
17 |
6.595 |
2013 |
|
TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis.
|
J Mol Cell Cardiol
23337087
|
45 |
5.68 |
2013 |
|
Adverse fibrosis in the aging heart depends on signaling between myeloid and mesenchymal cells; role of inflammatory fibroblasts.
|
J Mol Cell Cardiol
24184998
|
30 |
5.68 |
2013 |
|
AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction.
|
J Mol Cell Cardiol
23871790
|
23 |
5.68 |
2013 |
|
Myeloid growth factors.
|
J Natl Compr Canc Netw
24142827
|
24 |
4.675 |
2013 |
|
Moving forward with myeloid growth factors.
|
J Natl Compr Canc Netw
24142818
|
0 |
4.675 |
2013 |
|
Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803.
|
J Thorac Cardiovasc Surg
23768804
|
8 |
4.446 |
2013 |
|
Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
|
Lung Cancer
24396884
|
3 |
4.294 |
2013 |
|
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
|
Breast Cancer Res Treat
23771731
|
16 |
3.626 |
2013 |
|
State-to-state three-atom time-dependent reactive scattering in hyperspherical coordinates.
|
J Chem Phys
23406125
|
0 |
2.965 |
2013 |
|
Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies.
|
J Geriatr Oncol
24472473
|
9 |
2.852 |
2013 |
|
Routine completion axillary lymph node dissection for positive sentinel nodes in patients undergoing mastectomy is not associated with improved local control.
|
Am J Surg
23592166
|
4 |
2.612 |
2013 |
|
Serial ultrasound evaluation of pediatric trigger thumb.
|
J Pediatr Orthop
23482269
|
2 |
1.695 |
2013 |
|
Vasculogenic cytokines in wound healing.
|
Biomed Res Int
23555076
|
27 |
1.579 |
2013 |
|
Paroxysmal nocturnal hemoglobinuria: a red clot syndrome.
|
Ann Vasc Surg
24200143
|
0 |
1.145 |
2013 |
|
Prevention and treatment of chemotherapy-induced neutropenia.
|
Clin Adv Hematol Oncol
24518423
|
3 |
0 |
2013 |
|
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
|
J Clin Oncol
22547605
|
115 |
24.008 |
2012 |
|
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
|
Blood
23160462
|
16 |
13.164 |
2012 |
|
Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
|
Clin Cancer Res
22355011
|
0 |
9.619 |
2012 |
|
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
|
Gynecol Oncol
23262376
|
36 |
4.959 |
2012 |
|
Optimal management of malignant pleural effusions (results of CALGB 30102).
|
J Natl Compr Canc Netw
22878823
|
36 |
4.675 |
2012 |
|
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
|
Lung Cancer
22277104
|
13 |
4.294 |
2012 |
|
FcγRI mediates serum amyloid P inhibition of fibrocyte differentiation.
|
J Leukoc Biol
22493081
|
25 |
4.018 |
2012 |
|
New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.
|
Genes Chromosomes Cancer
23225546
|
5 |
3.696 |
2012 |
|
Origin of developmental precursors dictates the pathophysiologic role of cardiac fibroblasts.
|
J Cardiovasc Transl Res
22972312
|
26 |
2.319 |
2012 |
|
Adjuvant treatment of older patients with lung cancer.
|
Am Soc Clin Oncol Educ Book
24451756
|
0 |
0 |
2012 |
|
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
|
Leukemia
21321569
|
19 |
11.702 |
2011 |
|
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
|
J Thorac Oncol
21252718
|
5 |
6.595 |
2011 |
|
Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.
|
J Thorac Oncol
21857253
|
11 |
6.595 |
2011 |
|
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
|
Int J Radiat Oncol Biol Phys
21477940
|
15 |
5.133 |
2011 |
|
Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.
|
Crit Rev Oncol Hematol
21507676
|
10 |
4.971 |
2011 |
|
Myeloid growth factors.
|
J Natl Compr Canc Netw
21900221
|
18 |
4.675 |
2011 |
|
Small-cell lung cancer: prognostic factors and changing treatment over 15 years.
|
Clin Lung Cancer
22000695
|
45 |
3.434 |
2011 |
|
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
|
J Pain Symptom Manage
22104618
|
32 |
2.905 |
2011 |
|
Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer's disease neuropathology.
|
Neurochem Res
22205573
|
14 |
2.581 |
2011 |
|
Age- and sex-specific genomic profiles in non-small cell lung cancer.
|
JAMA
20145230
|
21 |
44.405 |
2010 |
|
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
|
J Clin Oncol
20385991
|
45 |
24.008 |
2010 |
|
Elafin is a biomarker of graft-versus-host disease of the skin.
|
Sci Transl Med
20371463
|
114 |
16.761 |
2010 |
|
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
|
J Thorac Oncol
20736856
|
37 |
6.595 |
2010 |
|
Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report.
|
J Thorac Oncol
20101153
|
5 |
6.595 |
2010 |
|
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.
|
Cancer
21509769
|
87 |
6.072 |
2010 |
|
The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design.
|
BMC Cancer
20409311
|
25 |
3.288 |
2010 |
|
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
|
Support Care Cancer
20191292
|
27 |
2.698 |
2010 |
|
Improved serum-free culture conditions for spleen-derived murine fibrocytes.
|
J Immunol Methods
20888336
|
25 |
2.34 |
2010 |
|
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
|
J Clin Oncol
19380447
|
28 |
24.008 |
2009 |
|
Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
|
Clin Cancer Res
19996213
|
4 |
9.619 |
2009 |
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
J Thorac Oncol
19652624
|
15 |
6.595 |
2009 |
|
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
|
Cancer
19025972
|
1 |
6.072 |
2009 |
|
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
|
Cancer
19672945
|
18 |
6.072 |
2009 |
|
Myeloid growth factors.
|
J Natl Compr Canc Netw
19176207
|
13 |
4.675 |
2009 |
|
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
|
Clin Colorectal Cancer
19203894
|
15 |
4.507 |
2009 |
|
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
|
Am J Clin Oncol
19433964
|
10 |
3.259 |
2009 |
|
Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation.
|
J Magn Reson Imaging
19937928
|
13 |
3.083 |
2009 |
|
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
|
J Clin Oncol
18757324
|
110 |
24.008 |
2008 |
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
|
Blood
18378853
|
65 |
13.164 |
2008 |
|
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
|
Clin Cancer Res
18223225
|
40 |
9.619 |
2008 |
|
Isolation and characterization of microsatellite loci in the beaver (Castor canadensis).
|
Mol Ecol Resour
21585849
|
1 |
7.332 |
2008 |
|
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
|
J Thorac Oncol
18379362
|
6 |
6.595 |
2008 |
|
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
|
J Thorac Oncol
18978566
|
1 |
6.595 |
2008 |
|
Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease.
|
J Thorac Oncol
18978575
|
1 |
6.595 |
2008 |
|
Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study.
|
Cancer
18988290
|
45 |
6.072 |
2008 |
|
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
|
J Natl Compr Canc Netw
18319047
|
86 |
4.675 |
2008 |
|
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
|
Lung Cancer
18255187
|
57 |
4.294 |
2008 |
|
Serum amyloid P inhibits dermal wound healing.
|
Wound Repair Regen
18318811
|
28 |
3.443 |
2008 |
|
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
|
J Clin Oncol
17634496
|
218 |
24.008 |
2007 |
|
Erythropoietin: high profile, high scrutiny.
|
J Clin Oncol
17312331
|
13 |
24.008 |
2007 |
|
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
|
J Clin Oncol
17577029
|
71 |
24.008 |
2007 |
|
A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
|
J Thorac Oncol
17410044
|
7 |
6.595 |
2007 |
|
A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
17545847
|
4 |
6.595 |
2007 |
|
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
|
Cancer
17705197
|
35 |
6.072 |
2007 |
|
Myeloid growth factors. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
17335688
|
14 |
4.675 |
2007 |
|
Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
|
Pharmacoeconomics
17402806
|
6 |
3.63 |
2007 |
|
May day.
|
Support Cancer Ther
18632478
|
0 |
0 |
2007 |
|
Update on neutropenia and myeloid growth factors.
|
J Support Oncol
17550054
|
0 |
0 |
2007 |
|
Highlights from: The 48th Annual Meeting of the American Society of Hematology; Orlando, FL.
|
Support Cancer Ther
18632471
|
0 |
0 |
2007 |
|
Hitting our stride.
|
Support Cancer Ther
18632514
|
0 |
0 |
2007 |
|
Cancer management in the era of targeted agents.
|
Support Cancer Ther
18632470
|
0 |
0 |
2007 |
|
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
|
J Clin Oncol
16682719
|
438 |
24.008 |
2006 |
|
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
|
J Clin Oncol
17075122
|
66 |
24.008 |
2006 |
|
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.
|
J Clin Oncol
17159190
|
49 |
24.008 |
2006 |
|
Targeting anemia in patients with lung cancer.
|
J Thorac Oncol
17409943
|
5 |
6.595 |
2006 |
|
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
|
Cancer
16575919
|
383 |
6.072 |
2006 |
|
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
|
Int J Radiat Oncol Biol Phys
16904841
|
7 |
5.133 |
2006 |
|
Small cell lung cancer clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
16813728
|
15 |
4.675 |
2006 |
|
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
|
Lung Cancer
17005294
|
1 |
4.294 |
2006 |
|
Erythropoiesis-stimulating protein support and survival.
|
Oncology (Williston Park)
16925111
|
0 |
3.963 |
2006 |
|
Colony-stimulating factor use in the context of refined risk and benefit assessments.
|
Oncology (Williston Park)
16736982
|
0 |
3.963 |
2006 |
|
Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
|
Oncology (Williston Park)
16736985
|
5 |
3.963 |
2006 |
|
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
|
Breast Cancer Res Treat
16705366
|
43 |
3.626 |
2006 |
|
Myelotoxicity from chemotherapy.
|
Semin Oncol
16473646
|
22 |
3.355 |
2006 |
|
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
|
Clin Drug Investig
17163259
|
1 |
1.853 |
2006 |
|
Disease management and patient-reported outcomes.
|
Support Cancer Ther
18632460
|
0 |
0 |
2006 |
|
Becoming a supportive cancer therapy generalist.
|
Support Cancer Ther
18632485
|
0 |
0 |
2006 |
|
Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.
|
J Support Oncol
16355556
|
4 |
0 |
2006 |
|
Support for supportive cancer therapy.
|
Support Cancer Ther
18632495
|
0 |
0 |
2006 |
|
The Role of Plerixafor (AMD3100) in Mobilizing Hematopoietic Progenitor Cells in Patients with Hematologic Malignancies.
|
Support Cancer Ther
18632442
|
1 |
0 |
2006 |
|
Integrating support into cancer therapy.
|
Support Cancer Ther
18632441
|
0 |
0 |
2006 |
|
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
|
J Clin Oncol
15837997
|
42 |
24.008 |
2005 |
|
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
|
Clin Cancer Res
16000612
|
3 |
9.619 |
2005 |
|
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?
|
Int J Radiat Oncol Biol Phys
15629595
|
21 |
5.133 |
2005 |
|
Myeloid growth factors clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
16038645
|
4 |
4.675 |
2005 |
|
Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
|
Value Health
15841893
|
4 |
4.235 |
2005 |
|
Regulatory effects of estrogen on acute lung inflammation in mice.
|
Am J Physiol Cell Physiol
15761213
|
61 |
3.602 |
2005 |
|
Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base.
|
Clin Lung Cancer
15943896
|
19 |
3.434 |
2005 |
|
Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
|
Clin Lung Cancer
16354314
|
3 |
3.434 |
2005 |
|
Improving the management of chemotherapy-induced neutropenia.
|
J Support Oncol
16108418
|
0 |
0 |
2005 |
|
Impact of erythropoietic agents on survival of anemic patients with cancer.
|
Support Cancer Ther
18628165
|
0 |
0 |
2005 |
|
Highlights from: The 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL.
|
Support Cancer Ther
18628173
|
0 |
0 |
2005 |
|
Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.
|
Support Cancer Ther
18632435
|
16 |
0 |
2005 |
|
Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
|
Curr Hematol Rep
16232380
|
0 |
0 |
2005 |
|
Improving clinical practice: the importance of guideline development.
|
Support Cancer Ther
18628161
|
0 |
0 |
2005 |
|
Highlights from: Third Annual Future of Supportive Therapy in Oncology, San Francisco, CA; 27th Annual, San Antonio Breast Cancer Symposium, San Antonio, TX; 46th Annual Meeting of the American Society of Hematology, San Diego, CA.
|
Support Cancer Ther
18628162
|
0 |
0 |
2005 |
|
A combined analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or filgrastim support.
|
Support Cancer Ther
18628178
|
1 |
0 |
2005 |
|
Exploring the breadth of supportive cancer care issues.
|
Support Cancer Ther
18628189
|
0 |
0 |
2005 |
|
Impact of the multinational association of supportive care in cancer on supportive cancer therapy.
|
Support Cancer Ther
18628172
|
0 |
0 |
2005 |
|
Year three of supportive cancer therapy.
|
Support Cancer Ther
18632426
|
0 |
0 |
2005 |
|
Deferasirox (ICL670; Exjade(R)), a Novel Orally Available Iron Chelator for Correction of Transfusion-Associated Iron Overload.
|
Support Cancer Ther
18628174
|
0 |
0 |
2005 |
|
Highlights from: The 46th Annual Meeting of the American Society of Hematology; San Diego, CA.
|
Support Cancer Ther
18628190
|
0 |
0 |
2005 |
|
Novel thrombopoetin mimetic agents with potential to ameliorate chemotherapy-induced thrombocytopenia.
|
Support Cancer Ther
18628164
|
0 |
0 |
2005 |
|
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
|
J Clin Oncol
15514374
|
7 |
24.008 |
2004 |
|
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
|
J Clin Oncol
15381684
|
90 |
24.008 |
2004 |
|
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
|
Cancer
14716755
|
275 |
6.072 |
2004 |
|
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
|
Int J Radiat Oncol Biol Phys
14967460
|
55 |
5.133 |
2004 |
|
The importance of chemotherapy dose intensity in lung cancer.
|
Semin Oncol
15726536
|
2 |
3.355 |
2004 |
|
Year two for supportive cancer therapy.
|
Support Cancer Ther
18628150
|
0 |
0 |
2004 |
|
One year of supportive cancer therapy.
|
Support Cancer Ther
18628141
|
0 |
0 |
2004 |
|
Impact of correction of anemia on clinical outcome in patients with cancer: recent data from head and neck and breast cancer trials.
|
Support Cancer Ther
18628135
|
3 |
0 |
2004 |
|
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
|
J Clin Oncol
14673039
|
126 |
24.008 |
2003 |
|
Activation of tyrosine kinases in cancer.
|
Oncologist
14657531
|
51 |
5.826 |
2003 |
|
Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
12738309
|
17 |
5.133 |
2003 |
|
Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.
|
Int J Radiat Oncol Biol Phys
12829134
|
22 |
5.133 |
2003 |
|
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.
|
J Natl Compr Canc Netw
19761076
|
25 |
4.675 |
2003 |
|
New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
|
J Natl Compr Canc Netw
19795580
|
0 |
4.675 |
2003 |
|
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
|
Semin Oncol
14508717
|
11 |
3.355 |
2003 |
|
Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
|
Pharmacotherapy
12921218
|
11 |
2.932 |
2003 |
|
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
|
Leuk Lymphoma
14959849
|
62 |
2.755 |
2003 |
|
Small-cell lung cancer: a review of clinical trials.
|
Semin Thorac Cardiovasc Surg
14710387
|
4 |
0 |
2003 |
|
Expanding the horizons of supportive therapy.
|
Support Cancer Ther
18628124
|
0 |
0 |
2003 |
|
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
|
J Clin Oncol
12377962
|
68 |
24.008 |
2002 |
|
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
|
Clin Cancer Res
12231521
|
13 |
9.619 |
2002 |
|
Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials.
|
Cancer
12209681
|
49 |
6.072 |
2002 |
|
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
|
Cancer
12209734
|
76 |
6.072 |
2002 |
|
Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
|
Drugs
12479597
|
4 |
5 |
2002 |
|
Anemia and lung cancer.
|
Lung Cancer
12468152
|
5 |
4.294 |
2002 |
|
Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
|
Oncology (Williston Park)
12380954
|
0 |
3.963 |
2002 |
|
Clinical benefits of epoetin alfa therapy in patients with lung cancer.
|
Clin Lung Cancer
14662041
|
2 |
3.434 |
2002 |
|
Neutrophil growth factors.
|
Curr Hematol Rep
12901130
|
3 |
0 |
2002 |
|
Family planning. Its pitfalls and administration.
|
Va Med Mon (1918)
5377565
|
0 |
0 |
1969 |
